Mexiletine and tocainide were administered to 79 pa• tients to determine whether the response to one of these drugs would predict the effect of the other. In 57 pa• tients, the two agents were evaluated noninvasively with monitoring and exercise testing, and efficacy was judged by the suppression of spontaneous ventricular arrhyth• mia. In the remaining 22 patients, electrophysiologic testing was performed and efficacy was defined as the inability to induce more than two repetitive ventricular premature beats. An equal number of patients reAvailable antiarrhythmic drugs do not possess distinctive electrophysiologic properties that help predict their clinical action. Selection of an effective drug demands individual evaluation of each agent. This is a time-consuming and costly undertaking. Therapy would be simplified if response to a particular drug could be reliably and expeditiously de• termined. It has been proposed that drugs with shared elec• trophysiologic properties in vitro may be grouped together (1). Such a classification of drugs implies that all the mem• bers of a group have c commonality of clinical effects on arrhythmia and can be used interchangeably. Indeed, it has been reported that a favorable effect obtained with procain• amide predicts a like response to quinidine, disopyramide, lidocaine and phenytoin (2) .
Tocainide and mexiletine are congeners of lidocaine with similar chemical structures and identical in vitro and in vivo electrophysiologic properties (3, 4) . Although both drugs sponded to mexiletine and tocainide (38 versus 39%). However, in only 42 patients (53 %) were the results concordant. There was no difference in concordance when the results were analyzed by method of drug evaluation, left ventricular ejection fraction or etiology of presenting arrhythmia. It is concluded that mexiletine and tocainide have different clinical effects and must be evaluated individually.
(J Am Coli CardioI1986; 7:338-43) have been reported to be effective for the treatment of ven• tricular arrhythmias (5) (6) (7) (8) , no studies have compared the action of these two drugs in the same group of patients. The purpose of this study was to determine whether one of these drugs predicts the response to the other.
Methods
Study patients. Seventy-nine consecutive patients, re• ferred for the management of life-threatening ventricular arrhythmias, were studied. The group consisted of 64 men and 15 women with a mean age of 56 years (range 23 to 79). Cardiac diagnoses included coronary artery disease in 53 patients, cardiomyopathy in 9 and valvular heart disease in 8. Nine patients had no structural heart disease as judged by cardiac catheterization and echocardiographic findings.
The presenting arrhythmia was ventricular fibrillation in 24 patients and ventricular tachycardia in 55 patients. In 41 of the latter 55 patients the tachycardia was sustained and associated with either syncope or presyncope. Nonsustained ventricular tachycardia associated with dizziness was the presenting arrhythmia in 14 of the 55 patients. In no case was the arrhythmia a consequence of acute myocardial in• farction or another reversible condition. In each patient pre• vious therapy with conventional drugs, including quinidine, procainamide, disopyramide and a beta-receptor blocker, was either not tolerated because of side effects or was in• effective despite blood levels in the defined therapeutic range.
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Baseline evaluation. On hospital admission all antiar• rhythmic agents were discontinued and patients were con• tinuously monitored by telemetry (CAMS, American Op• tical) (9, 10) . Digoxin and diuretic drugs were continued for control of congestive heart failure. Antianginal medications were not altered during drug evaluation. After a washout period of at least 36 hours, patients underwent 48 hours of continuous ambulatory monitoring (II) and a maximal symptom-limited exercise tolerance test performed on a mo• torized treadmill in accordance with the Bruce protocol (12) . This constituted the control period. in which the frequency, type and reproducibility of spontaneous arrhythmia were evaluated.
Ventricular arrhythmia was categorized by the Lown grading system (13) (14) . Electrophysiologic testing. A 6F USCI hexapolar elec• trode catheter was inserted by way of the left subclavian vein under fluoroscopic guidance and positioned in the right ventricular apex. One, two or three extrastimuli were se• quentially added during both sinus and ventricular paced rhythms at a cycle length of 500 ms. The current strengths of extrastimuli were two and three times the mid-diastolic threshold. The number of stimuli utilized was increased until an end point was induced. The end point for testing was nonsustained or sustained ventricular tachycardia that re• sembled the clinical arrhythmia. Nonsustained ventricular tachycardia was defined as three or more repetitive responses lasting up to 30 seconds, while sustained ventricular tachy• cardia was defined as an arrhythmia persisting for more than 30 seconds. We (14) and other investigators (15) (16) (17) have used non sustained ventricular tachycardia as an end point for drug selection as distinct from the use of this technique to predict risk. Drug therapy. At the conclusion of control studies therapy with either tocainide or mexiletine was initiated i~ the following manner for those undergoing a noninvasive protocol. The oral dose of tocainide was 400 mg and that of mexiletine was 200 mg; each was administered three times daily. Daily dosage was increased every 24 hours if the arrhythmia persisted and no adverse effects supervened. The. ~aximal daily dose administered was 2,400 mg of tocalmde and 1,200 mg of mexiletine. After at least 4 days of therapy, ambulatory electrocardiographic monitoring and exercise testing were repeated. Criteria for drug efficacy during monitoring and exercise testing included the follow• ing: I) a greater than 90% reduction in the frequency of ventricular tachycardia (grade 4B) and couplets (grade 4A), and 2) a greater than 50% decrease in grade 2 ventricular premature beats. For a drug to be judged effective with noninvasive evaluation. both monitoring and exercise cri• teria for efficacy had to be met. Drug dosing in patients undergoing electrophysiologic testing followed a similar schedule to that outlined, and the dose was titrated on the basis of side effects. After 4 days of therapy with one agent, electrophysiologic studies were repeated. The criterion for efficacy by this method was inability to provoke three or more repetitive responses dur• ing sinus rhythm and ventricular pacing after administration of three sequential extrastimuli. We (14) have previously reported the use of this end point for defining drug efficacy. Because it is not certain that conversion of sustained to nonsustained ventricular tachycardia represents a drug re• sponse, we used a more rigorous criterion for drug efficacy. Blood/or drug levels was obtained 2 hours after dosing, at the time the exercise test or electrophysiologic study was performed. At the conclusion of evaluation with one drug, a 24 hour washout period intervened before the second agent was initiated. The dose was titrated as described earlier.
Patients received the drugs in no consistent order.
Statistical analysis was performed by the chi-square method. The criterion for significance was probability (p) less than 0.05.
Results
Tocainide and mexiletine were equally effective in the 79 patients. Mexiletine was effective in 30 patients (38%) and tocainide in 31 (39%) ( Table 1) . Patients who did not respond showed no significant change in the frequency of ventricular premature beats or repetitive forms. In patients whose arrhythmia remained inducible during electrophysi• ologic testing, the same end point was induced and cycle length was not significantly altered. Both drugs were ef• fective in 12 patients (15%) and ineffective in 30 patients (38%). Thus the results of therapy with the two agents were concordant in 42 (53%) of the 79 patients (Table 2 ). In 19 patients only tocainide was effective while in 18 only mex• iletine suppressed arrhythmia. Blood levels did not distin• guish responders from nonresponders; with mexiletine the respective values were 1.8 and 1.9 JLg/ml and with tocainide they were 9.1 and 8.8 JLg/ml.
Noninvasive versus invasive findings. Of the 57 pa• tients who underwent noninvasive testing, 52% had a con• cordant result. When the responses during ambulatory mon• itoring and exercise testing were evaluated independently, concordance was the same. This was similar to the 55% concordance encountered in the 22 patients subjected to electrophysiologic studies (Table 3 ). There was no differ• ence in concordance when test results were analyzed by end point achieved, that is, sustained or nonsustained ventricular tachycardia. The method of drug evaluation--:noninvasive or invasive studies-was not helpful in predicting response to either tocainide or mexiletine. Analysis based on the etiology of the presenting arrhythmia, whether nonsustained or sustained ventricular tachycardia, similarly failed to im• prove the degree of concordance (Table 4) .
Ejection fraction. Left ventricular ejection fraction was assessed in 62 patients by either contrast or radionuclide angiography and was greater than 40% (mean 55%) in 24 patients and less than 40% (mean 25%) in 38 patients. In 46% of patients with an ejection fraction greater than 40%, the tocainide and mexiletine responses were concordant, whereas they were concordant in 58% of patients with an ejection fraction of less than 40% (Table 5) , Tocainide and mexiletine were of equal efficacy irrespective of the ejection fraction. However, greater efficacy of both drugs was ob• served in patients with an ejection fraction greater than 40% (p < 0.05) ( Table 6 ). Mexiletine was effective in II (46%) of 24 patients with a left ventricular ejection fraction greater than 40% and tocainide was effective in 12 (50%) of 24 such patients. In contrast, when ejection fraction was less than 40%, the drugs were effective in II (29%) of 38.
Discussion
Therapy for ventricular arrhythmia is empiric, without practical clinical guidelines for predicting drug response. Although there is controversy about how to evaluate drug efficacy, it has been reported (10,18) that therapy with an• tiarrhythmic drugs will prevent recurrent tachyarrhythmia when spontaneous arrhythmia is suppressed or induced ar• rhythmia cannot be provoked. However, establishing an effective drug program is a time-consuming and costly pro• cess. The ability to predict with certainty the effectiveness of a particular drug would improve the process of drug selection, Mexiletine versus tocainide. Classifying antiar• rhythmic drugs on the basis of their electrophysiologic prop• erties is a widely accepted practice (1). The assumption is that drugs with similar electrophysiologic actions may have similar clinical antiarrhythmic effects. Mexiletine and to• cainide are ideal candidates to support this hypothesis. They are both lidocaine congeners and structurally resemble each other. As membrane stabilizing agents, classified as I B drugs, they decrease membrane conductivity and shorten action potential duration. They have little effect on the re• fractory period; however, the ratio of refractory period to action potential duration is increased, resulting in a reduc• tion of membrane excitability. They share similar phar-macologic properties and cause the same type of toxicity, In this study, tocainide and mexiletine were equally effective in a group of patients with refractory sustained ventricular tachyarrhythmias. Surprisingly, the response to these two agents was similar in only 53% of patients. Analysis based on method of evaluating drug effect on presenting arrhyth• mia or left ventricular function did not improve the con• cordance. Concordance of response tended to be greater in patients with a left ventricular ejection fraction of less than 40% than in patients with an ejection fraction greater than 40% (58 versus 46%), but this difference was not statisti• cally significant. This result was largely due to the fact that in patients with a decreased left ventricular ejection fraction both drugs were more often ineffective than they were in patients with a higher ejection fraction. Mexiletine and to• cainide are therefore clinically different from each other and the antiarrhythmic effect of one drug is not predicted by the response to the other. Each drug must be evaluated individually.
Concordance of response between related antiar• rhythmic agents. Only a few studies have reported cor• relation of response to related agents, and their results are conflicting, Waxman et a1. (2) reported that the response to intravenous procainamide predicted the response to other membrane-active agents of the same class, specifically quin• idine, disopyramide, lidocaine and phenytoin. Twenty-five (83%) of 30 patients whose arrhythmia was non inducible when receiving intravenous procainamide responded to at least one other drug. These 30 patients underwent 67 drug studies and in 43 studies (64%) the drug was effective. In contrast, 69 patients unresponsive to procainamide under• went 145 drug studies. In only nine patients (13%) and in 10 studies (7%) was another agent effective. The authors concluded that failure to respond to intravenous procain• amide eliminated the need to evaluate other conventional agents. There are a number of inadequacies in this retro• spective study. Drug levels were available in only a minority of patients. As reported, disopyramide blood levels were significantly lower in nonresponders than in responders (p = 0.01). An additional limitation was that lidocaine, quinidine, disopyramide and phenytoin were not evaluated (19) (20) (21) .
Other investigators have reported different results
Oseran et al. (19) noted that of 11 patients whose arrhythmia remained inducible during administration of intravenous procainamide. 6 responded to oral procainamide or oral quinidine. Thus, intravenous procainamide was predictive in only 45% of patients. Wyse et al. (20) noted that pro• cainamide did not predict the response to quinidine or di• sopyramide in 6 (26%) of 23 patients. In a group of 98 patients, Rae et al. (22) reported that failure to respond to procainamide did not predict response to other agents. The lack of concordance in antiarrhythmic efficacy among quin• idine, procainamide and disopyramide might be explained by their dissimilar chemical structures. When two very sim• ilar drugs such as lidocaine and tocainide are compared. concordance is improved but does not accurately predict drug effectiveness in all patients.
In our previous experience (5) with a group of 50 patients treated with both of these agents in random sequence. lid• ocaine predicted tocainide response in 78%. However, a negative response to lidocaine was more helpful than a pos• itive response. Of 27 patients who failed to respond to lidocaine. 23 (85%) did not respond to tocainide. In contrast. of the 14 patients responding to lidocaine. 12 (63%) also responded to tocainide. Similar results were reported by Winkle et al. (23) in a group of 26 patients.
Factors affecting concordance of drug response. In studying the concordance rates of two antiarrhythmic drugs, one must be attentive to the prevalence of severe heart disease in the population sample. If the sample is skewed owing to a preponderance of patients with markedly im• paired ventricular dysfunction, a spuriously high concord• ance rate will be observed, in part because antiarrhythmic drug efficacy is reduced in patients with substantial myo• cardial compromise. In the present study, drug effectiveness was directly related and the concordance rate inversely re• lated to ejection fraction. Among patients with ventricular tachycardia and an ejection fraction greater than 40%, the response to either mexiletine or tocainide was 50% and the concordance for the two drugs was also 50%; however, in those with an ejection fraction of less than 40%, efficacy of either agent was approximately 30% whereas concord• ance was 65%.
Classification of antiarrhythmic drugs is based on their electrophysiologic properties, but clinical effects may differ. The reason for this is not clear but may be due to differences in tissue binding, metabolism, clearance and effects of me• tabolites. Even structurally identical agents, which are only Conclusions. In this study we have demonstrated that mexiletine and tocainide are both effective antiarrhythmic agents, However. the response to one of these drugs will not predict the effect of the other. Therefore. these agents have different clinical effects and each must be evaluated individually,
